Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

165 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of the Anti-C1s Humanized Antibody TNT009 and Its Parental Mouse Variant TNT003 on HLA Antibody-Induced Complement Activation-A Preclinical In Vitro Study.
Wahrmann M, Mühlbacher J, Marinova L, Regele H, Huttary N, Eskandary F, Cohen G, Fischer GF, Parry GC, Gilbert JC, Panicker S, Böhmig GA. Wahrmann M, et al. Among authors: gilbert jc. Am J Transplant. 2017 Sep;17(9):2300-2311. doi: 10.1111/ajt.14256. Epub 2017 Mar 31. Am J Transplant. 2017. PMID: 28251805 Free PMC article.
Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trial.
Eskandary F, Jilma B, Mühlbacher J, Wahrmann M, Regele H, Kozakowski N, Firbas C, Panicker S, Parry GC, Gilbert JC, Halloran PF, Böhmig GA. Eskandary F, et al. Among authors: gilbert jc. Am J Transplant. 2018 Apr;18(4):916-926. doi: 10.1111/ajt.14528. Epub 2017 Oct 31. Am J Transplant. 2018. PMID: 28980446 Free article. Clinical Trial.
Blockade of HLA Antibody-Triggered Classical Complement Activation in Sera From Subjects Dosed With the Anti-C1s Monoclonal Antibody TNT009-Results from a Randomized First-in-Human Phase 1 Trial.
Mühlbacher J, Jilma B, Wahrmann M, Bartko J, Eskandary F, Schörgenhofer C, Schwameis M, Parry GC, Gilbert JC, Panicker S, Böhmig GA. Mühlbacher J, et al. Among authors: gilbert jc. Transplantation. 2017 Oct;101(10):2410-2418. doi: 10.1097/TP.0000000000001804. Transplantation. 2017. PMID: 28926521 Free PMC article. Clinical Trial.
A Randomized, First-in-Human, Healthy Volunteer Trial of sutimlimab, a Humanized Antibody for the Specific Inhibition of the Classical Complement Pathway.
Bartko J, Schoergenhofer C, Schwameis M, Firbas C, Beliveau M, Chang C, Marier JF, Nix D, Gilbert JC, Panicker S, Jilma B. Bartko J, et al. Among authors: gilbert jc. Clin Pharmacol Ther. 2018 Oct;104(4):655-663. doi: 10.1002/cpt.1111. Epub 2018 Jul 13. Clin Pharmacol Ther. 2018. PMID: 29737533 Free PMC article. Clinical Trial.
Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial.
Jäger U, D'Sa S, Schörgenhofer C, Bartko J, Derhaschnig U, Sillaber C, Jilma-Stohlawetz P, Fillitz M, Schenk T, Patou G, Panicker S, Parry GC, Gilbert JC, Jilma B. Jäger U, et al. Among authors: gilbert jc. Blood. 2019 Feb 28;133(9):893-901. doi: 10.1182/blood-2018-06-856930. Epub 2018 Dec 17. Blood. 2019. PMID: 30559259 Free PMC article. Clinical Trial.
Specific Inhibition of the Classical Complement Pathway Prevents C3 Deposition along the Dermal-Epidermal Junction in Bullous Pemphigoid.
Freire PC, Muñoz CH, Derhaschnig U, Schoergenhofer C, Firbas C, Parry GC, Panicker S, Gilbert JC, Stingl G, Jilma B, Heil PM. Freire PC, et al. Among authors: gilbert jc. J Invest Dermatol. 2019 Dec;139(12):2417-2424.e2. doi: 10.1016/j.jid.2019.04.025. Epub 2019 Jun 20. J Invest Dermatol. 2019. PMID: 31229501 Free article. Clinical Trial.
165 results